Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 150 million

GOTHENBURG, Sweden, May 14, 2020 – Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the “Company”) Board of Directors resolved on May 7, 2020, on a fully guaranteed new share issue of a maximum of 42,739,736 shares with preferential rights for the Company’s existing shareholders (the “Rights Issue”). Through the Rights Issue, the Company will receive approximately SEK 150 million before transaction costs related to the Rights Issue. In connection with the Rights Issue, the Company publishes a prospectus which today has been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen).

Not for publication, distribution or release, directly or indirectly, in whole or in part, within or into the US, Canada, Japan, Australia, Hong Kong, New Zeeland or any other jurisdiction in which such publication, distribution or release may be contravening to any applicable laws or rules. Additional restrictions are applicable, please see “Important information” in the end of this press release.
 

Timetable for the Rights Issue

Record date for participation in the Rights IssueMay 14, 2020
Subscription periodMay 18 June 1, 2020
Trading in subscription rightsMay 18 – May 28, 2020
Trading in BTAs May 18 June 3, 2020
Announcement of final outcome in the Rights IssueAround June 3, 2020
Delivery of and trading in new shares subscribed with subscription rightsAround June 9, 2020
Delivery of and trading in new shares subscribed without subscription rightsAround June 18, 2020

 

Prospectus

For full information regarding the Rights Issue, please refer to the prospectus, which is available on Isofol´s website, www.isofolmedical.com. Link to the application form is available on the same link at the start of the subscription period at the latest, and on Carnegie Investment Bank AB (publ)’s website, www.carnegie.se. The prospectus is also available on www.fi.se.

For further information, please contact

Isofol Medical AB (publ)
Jarl Ulf Jungnelius, M.D., Chief Executive Officer
E-mail:
jungnelius@isofolmedical.com
Mobil: +46 (0) 709 16 89 55

Certified Adviser
FNCA Sweden AB
E-mail: info@fnca.se
Phone: +46 (0)8 528 003 99

The information was submitted for publication through the agency of the Company’s CEO at 13.45 CET on May 14, 2020.

About arfolitixorin

Arfolitixorin is Isofol’s proprietary drug candidate being developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer. The drug candidate is currently being studied in a global Phase 3 study, AGENT. As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit all patients with advanced colorectal cancer, as it does not require complicated metabolic activation to become effective.

About Isofol Medical AB (publ)

Isofol Medical AB (publ) is a clinical stage biotech company developing arfolitixorin to improve the efficacy of standard of care chemotherapy for advanced colorectal cancer by increasing tumor response and progression free survival. Isofol holds a worldwide exclusive license agreement with Merck KGaA, Darmstadt, Germany to develop and commercialize arfolitixorin for oncology indications. Isofol Medical AB is traded on the Nasdaq First North Premier Growth Market. Certified Adviser is FNCA Sweden AB

Important information

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in Isofol in any jurisdiction, not from Isofol or from any other person.

The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Hong Kong, Japan, Canada, New Zeeland, the United States, or in any other jurisdiction where such announcement, publication or distribution of the information may not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law.

The securities referred to herein have not and will not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States.

www.isofolmedical.com

For further information, please contact

Document